Farmaceutica Remedia SA

As of June 30, 2026, Farmaceutica Remedia SA carries a market capitalization of 76.46M, placing it among publicly traded companies globally. Its enterprise value stands at 38.52M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Farmaceutica Remedia SA has 93.70M shares outstanding.

As of June 30, 2026, Farmaceutica Remedia SA trades at a trailing price-to-earnings ratio of 19.23. The price-to-sales ratio is 0.10, and the price-to-book ratio stands at 1.04.

As of June 30, 2026, Farmaceutica Remedia SA trades at an EV/EBITDA multiple of 3.50 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.05 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 4.62 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 38.52M versus a market cap of 76.46M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Farmaceutica Remedia SA maintains a current ratio of 1.10, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.79, indicating moderate leverage, while an interest coverage ratio of -890.46 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Farmaceutica Remedia SA posted a return on equity (ROE) of 5.42, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 4.32 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.13, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.37, useful for judging operating efficiency across full business cycles. The company generates approximately 3.44M in revenue per employee across its workforce of 215.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 12.74 indicates how many times Farmaceutica Remedia SA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Farmaceutica Remedia SA recorded 6.20M in income tax expense. That works out to an effective tax rate of 60.86, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 10.19M, leaving 3.99M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Farmaceutica Remedia SA's stock has gained approximately 9.66% over the past 52 weeks. The 50-day moving average sits at 0.79, while the 200-day moving average is 0.84.

Over the twelve months ended June 30, 2026, Farmaceutica Remedia SA generated 739.51M in revenue and converted that into 3.99M in net income, yielding earnings per share of 0.04. EBITDA reached 10.99M, while operating income came in at 8.40M.

As of June 30, 2026, Farmaceutica Remedia SA holds 38.52M in cash and equivalents against 581,784.00 in total debt, resulting in a net debt position of -38.52M. Total book value stands at 73.50M, with working capital of 27.16M providing operational flexibility.

Over the twelve months ended June 30, 2026, Farmaceutica Remedia SA posted a gross margin of 7.98, reflecting its pricing power and cost economics. The operating margin of 1.14 and net profit margin of 0.54 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Farmaceutica Remedia SA paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 5.22, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Farmaceutica Remedia SA shareholders.

As of June 30, 2026, Farmaceutica Remedia SA has an Altman Z-Score of 2.56, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.